When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to ...

A key enzyme and its molecular pathway are critical to keeping certain immune cells active and away from "exhaustion," ...

A key enzyme and its molecular pathway are critical to keeping activated CD8+ T cells active and away from “exhaustion”, ...

A rapidly developed, dual-target chimeric antigen receptor T-cell therapy produced a 100% overall response rate in patients ...

Second of 2 parts featuring an interview with Stephen Strickland, MD, MSCI,director, Leukemia Research for Sarah Cannon ...

Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising ...

Q1 2025 Earnings Call Transcript May 12, 2025 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is ...

Our trial provides proof of concept that cytokine-armored CAR T-cell treatment is feasible and may enhance antitumor activity without additional toxic effects,” researchers reported.

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online ...

Cambridge, Massachusetts Saturday, May 10, 2025, 18:00 Hrs [IST] ...

Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal ...

These receptors allow T cells to sense and respond ... Activated T cells undergo metabolic reprogramming to optimize effector functions, but the underlying mechanisms remain elusive.